This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Orphan designation: amitriptyline Treatment of erythromelalgia, 21/06/2022 Withd...
Orphan designation: Adeno-associated viral vector serotype 9 containing the huma...
Orphan designation: Adeno-associated virus serotype 5 vector encoding C1-esteras...
Orphan designation: xevinapant Treatment of ovarian cancer, 11/11/2015 Withdrawn
Orphan designation: volixibat potassium Treatment of primary biliary cholangitis...
Human medicines European public assessment report (EPAR): Imfinzi, durvalumab, D...
Orphan designation: Allogenic umbilical cord-derived osteoblast cells Treatment ...
Orphan designation: Elraglusib Treatment of soft tissue sarcoma, 16/01/2025 Posi...
Orphan designation: [4-(Methyl-1H-pyrazol-4-yl)-benzyl]-(6[7-(3-pyrrolidin-1-yl-...
DARWIN EU data partners onboarded in phases I, II and III
Orphan designation: Elraglusib Treatment of pancreatic cancer, 16/01/2025 Positive
Orphan designation: Alvelestat Treatment of congenital alpha-1 antitrypsin defic...
Orphan designation: Camostat mesilate Treatment of chronic pancreatitis, 16/01/2...
Human medicines European public assessment report (EPAR): Saxenda, liraglutide, ...
Data Analysis and Real World Interrogation Network (DARWIN EU)
Human medicines European public assessment report (EPAR): Sapropterin Dipharma, ...
DARWIN EU: Making health data count
Human medicines European public assessment report (EPAR): Yesintek, ustekinumab,...
DARWIN EU data partners onboarded in phases I and II
DARWIN EU Advisory Board meeting: 3 May 2024, Online, European Medicines Agency,...
Minutes - DARWIN EU Advisory Board - 3 May 2024
Human medicines European public assessment report (EPAR): Qaialdo, spironolacton...
Human medicines European public assessment report (EPAR): Memantine Mylan, meman...
Human medicines European public assessment report (EPAR): Jakavi, ruxolitinib, D...